Back To: Home

January 19-23, 2015
PepTalk - San Diego, CA

February 7-11, 2015
SLAS2015 - Washington, DC

More Events

Amgen, Predix to collaborate
by Randall C. Willis  |  Email the author

LEXINGTON, Mass.Predix Pharmaceuticals announced the signing of an exclusive collaboration and licensing agreement with Amgen for the development of compounds to treat a variety of autoimmune diseases. In particular, the companies will work on existing Predix preclinical compounds and novel S1P1 modulators.
"This collaboration provides Predix with the option to transform into a fully integrated pharmaceutical company by exercising our co-promote option with Amgen," said Chen Schor, chief business officer of Predix. "This deal comes as we are in the process of finalizing our merger with EPIX [Pharmaceuticals] and will further enable the combined company to pursue this research program along with our other development programs."
Initially, Predix will receive an infusion of $20 million, but this could expand to more than $300 million if certain clinical, regulatory and sales milestones are met. The company may also receive double-digit royalties on future sales of resulting products, and will have the option to promote these products to specialty physicians in the United States.


Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2014 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.